Abstract

Thrombin exosite 1 binds the predominant gamma(A)/gamma(A)-fibrin form with low affinity. A subpopulation of fibrin molecules, gamma(A)/gamma'-fibrin, has an extended COOH terminus gamma'-chain that binds exosite 2 of thrombin. Bivalent binding to gamma(A)/gamma'-fibrin increases the affinity of thrombin 10-fold, as determined by surface plasmon resonance. Because of its higher affinity, thrombin dissociates 7-fold more slowly from gamma(A)/gamma'-fibrin clots than from gamma(A)/gamma(A)-fibrin clots. After 24 h of washing, however, both gamma(A)/gamma'- and gamma(A)/gamma(A)-fibrin clots generate fibrinopeptide A when incubated with fibrinogen, indicating the retention of active thrombin. Previous studies demonstrated that heparin heightens the affinity of thrombin for fibrin by simultaneously binding to fibrin and exosite 2 on thrombin to generate a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin and heparin cofactor II. In contrast, dermatan sulfate does not promote ternary complex formation because it does not bind to fibrin. Heparin-catalyzed rates of thrombin inhibition by antithrombin were 5-fold slower in gamma(A)/gamma'-fibrin clots than they were in gamma(A)/gamma(A)-fibrin clots. This difference reflects bivalent binding of thrombin to gamma(A)/gamma'-fibrin because (a) it is abolished by addition of a gamma'-chain-directed antibody that blocks exosite 2-mediated binding of thrombin to the gamma'-chain and (b) the dermatan sulfate-catalyzed rate of thrombin inhibition by heparin cofactor II also is lower with gamma(A)/gamma'-fibrin than with gamma(A)/gamma(A)-fibrin clots. Thus, bivalent binding of thrombin to gamma(A)/gamma'-fibrin protects thrombin from inhibition, raising the possibility that gamma(A)/gamma'-fibrin serves as a reservoir of active thrombin that renders thrombi thrombogenic.

Highlights

  • Grants MOP 3992 and CTP 79846, Heart and Stroke Foundation of Ontario Grants T4729 and T4730, and funds from the Ontario Research and Development Challenge Fund

  • This study (a) confirms that ␥A/␥Ј-fibrin binds thrombin with higher affinity than ␥A/␥A-fibrin, (b) demonstrates that thrombin bound to ␥A/␥Ј-fibrin is protected from inhibition by antithrombin to a greater extent than thrombin bound to ␥A/␥A-fibrin, and (c) shows that ␥A/␥Ј-fibrin serves as a reservoir of active thrombin, which may contribute to the prothrombotic nature of thrombi

  • Previous work suggested that the mechanism by which thrombin within the ternary heparin-thrombin-fibrin complex is protected from inhibition reflects the inability of antithrombin-bound heparin to access exosite 2 of thrombin, thereby precluding essential bridging of enzyme and inhibitor by heparin [16]

Read more

Summary

Introduction

Grants MOP 3992 and CTP 79846, Heart and Stroke Foundation of Ontario Grants T4729 and T4730, and funds from the Ontario Research and Development Challenge Fund. Fraser Mustard Endowed Chair in Cardiovascular Research, and Canada Research Chair (Tier 1) in Thrombosis. Exosite 2 mediates the binding of thrombin to GP 1b␣ on the platelet surface or to the chondroitin sulfate moiety of thrombomodulin on the endothelial cell surface [6, 7]. A subset of fibrin molecules binds thrombin with 10- to 20-fold higher affinity than the bulk fraction [10, 11] These fibrin molecules, which possess a variant form of the ␥A-chain with an extended COOH terminus that is designated ␥Ј, are termed ␥A/␥Ј [12]. Thrombin binds to this ␥Ј-chain extension via exosite 2 [13, 14].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call